Lyme Disease Persister Cells: Why Bacteria Survive Antibiotics
Lyme disease persister cells may explain why some patients remain ill even after antibiotic treatment. Experimental studies have demonstrated persistent infection of Borrelia burgdorferi in multiple animal models, including mice, dogs, and non-human primates. :contentReference[oaicite:0]{index=0}
Some researchers argue that persistent infection may underlie chronic symptoms in Lyme disease patients. In fact, studies suggest that up to one-third of treated patients remain chronically ill.
In a review published in the Bosnian Journal of Basic Medical Sciences, Dr. Emir Hodzic explored how “persister” cells contribute to antibiotic tolerance and prolonged infection.
What Are Persister Cells?
“The main culprit responsible for the tolerance of pathogens to antibiotics is a specialized survivor—a persister,” explains Hodzic.
Persister cells are dormant, non-growing bacteria that evade antibiotics. Because most antibiotics target actively dividing cells, these dormant forms survive treatment.
As a result, persisters cannot be easily eliminated or cultured using standard laboratory methods.
How Borrelia Develops Antibiotic Tolerance
During infection, Borrelia burgdorferi can generate weakened (attenuated) spirochetes that have lost plasmids—small DNA structures essential for normal replication.
These altered bacteria:
- Divide slowly or not at all
- Remain viable within the host
- Become tolerant to antibiotics
- Are often non-cultivable
This slow-growing or dormant state allows Borrelia to survive antimicrobial therapy.
Spirochetes visualized in tissue 12 months after antibiotic treatment.
Evidence of Persistence After Treatment
Hodzic reported that non-cultivable Borrelia spirochetes reappeared in mouse tissues 12 months after antibiotic treatment.
“There is clear scientific evidence that a small, heterogeneous subpopulation of surviving spirochetes shows tolerance to antimicrobial agents and can persist in a host for a prolonged period,” he states.
Importantly, persister cells may not appear immediately—they can emerge months after treatment, contributing to delayed or recurrent symptoms.
Why Early Treatment Matters
Borrelia is highly prone to plasmid loss over time, which increases the likelihood of developing antibiotic-tolerant forms.
This may explain why treatment is more effective during early infection—before persister populations become established.
Delayed treatment may allow persister cells to develop, making infection more difficult to eradicate.
Environmental and Transmission Considerations
Persister organisms are not limited to humans. They have been identified in animals, insects, rodents, and migratory birds.
Antimicrobial tolerance can develop in environments where antibiotics are present, including natural ecosystems.
Transmission of antimicrobial-tolerant organisms from animals to humans has been documented in other infections, raising concerns about similar mechanisms in Lyme disease.
Why Persisters Matter Clinically
The presence of persister cells may explain why some patients do not respond fully to antibiotic therapy.
Unlike antibiotic resistance, persister-related tolerance affects multiple classes of antibiotics and does not depend on genetic resistance mechanisms.
This means that standard antibiotic regimens may fail to eliminate all forms of the bacteria.
Clinical Perspective
Lyme disease persister cells represent an important mechanism that may contribute to persistent symptoms after treatment.
Understanding persister biology is essential to developing more effective treatment strategies and improving outcomes for patients with chronic Lyme disease.
Further research is needed to better understand how these cells survive and how they can be targeted therapeutically.
Sources:
- Schwan TG et al. J Clin Microbiol, 1988.
- Barthold SW et al. Am J Pathol, 1993.
- Moody KD et al. Am J Trop Med Hyg, 1990.
- Goodman JL et al. J Clin Microbiol, 1991.
- Preac Mursic V et al. Infection, 1990.
- Sonnesyn SW et al. Infect Immun, 1993.
- Straubinger RK et al. J Clin Microbiol, 1997.
- Roberts ED et al. Lab Invest, 1995.
- Cameron DJ et al. Expert Rev Anti Infect Ther, 2014.
- Hodzic E. Bosn J Basic Med Sci, 2015.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
